Compare · CRMD vs OUST
CRMD vs OUST
Side-by-side comparison of CorMedix Inc. (CRMD) and Ouster Inc. (OUST): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while OUST operates in Industrials - the two are in different parts of the market.
- OUST is the larger of the two at $518.2M, about 3.3x CRMD ($155.0M).
- Over the past year, CRMD is down 23.1% and OUST is up 26.4% - OUST leads by 49.6 points.
- OUST has been more active in the news (9 items in the past 4 weeks vs 2 for CRMD).
- OUST has more recent analyst coverage (18 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- Ouster Inc.
- Price
- $8.41+1.45%
- $37.01+5.37%
- Market cap
- $155.0M
- $518.2M
- 1M return
- -2.89%
- -13.25%
- 1Y return
- -23.13%
- +26.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 2
- 9
- Recent ratings
- 7
- 18
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Latest CRMD
- CorMedix Inc. filed SEC Form 8-K: Other Events
- CorMedix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant
- SEC Form S-8 POS filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
- Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Latest OUST
- Defiance Launches OUSL: The First Daily 2X Long ETF for Ouster, Inc.
- Ouster Announces Date for Second Quarter 2026 Earnings Call
- Director Heystee Susan was granted 660 shares, increasing direct ownership by 2% to 40,479 units (SEC Form 4)
- SEC Form 8-K filed by Ouster Inc.
- SEC Form 424B5 filed by Ouster Inc.
- Ouster, Inc. Announces Pricing of Public Offering of Common Stock
- SEC Form 424B5 filed by Ouster Inc.
- SEC Form S-3ASR filed by Ouster Inc.
- Ouster Announces Build America, Buy America Compliance for REV8 OS Digital Lidar Sensors
- Director Skaggs Stephen A was granted 4,725 shares, increasing direct ownership by 8% to 66,415 units (SEC Form 4)